Outlook Therapeutics, Inc. (OTLK)

USD 1.4

(-2.78%)

Market Cap (In USD)

33.11 Million

Revenue (In USD)

-

Net Income (In USD)

-58.98 Million

Avg. Volume

231.08 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.87-12.85
PE
-
EPS
-
Beta Value
0.63
ISIN
US69012T3059
CUSIP
69012T206
CIK
1649989
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. C. Russell Trenary III
Employee Count
-
Website
https://www.outlooktherapeutics.com
Ipo Date
2016-06-14
Details
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.